SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-325269
Filing Date
2021-11-10
Accepted
2021-11-10 07:29:07
Documents
14
Period of Report
2021-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d228442d8k.htm   iXBRL 8-K 26859
2 EX-99.1 d228442dex991.htm EX-99.1 103156
6 GRAPHIC g228442dsp1.jpg GRAPHIC 7487
  Complete submission text file 0001193125-21-325269.txt   281806

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tsha-20211110.xsd EX-101.SCH 2883
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tsha-20211110_lab.xml EX-101.LAB 18888
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tsha-20211110_pre.xml EX-101.PRE 11854
7 EXTRACTED XBRL INSTANCE DOCUMENT d228442d8k_htm.xml XML 3474
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

IRS No.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39536 | Film No.: 211394402
SIC: 2836 Biological Products, (No Diagnostic Substances)